about
Towards the Manufacture of Megakaryocytes and Platelets for Clinical Application.Variants of a Thermus aquaticus DNA polymerase with increased selectivity for applications in allele- and methylation-specific amplification.Scoring HLA class I mismatches by HistoCheck does not predict clinical outcome in unrelated hematopoietic stem cell transplantation.The c.503T>C Polymorphism in the Human KLRB1 Gene Alters Ligand Binding and Inhibitory Potential of CD161 Molecules.miR-145 Contributes to Hypertrophic Scarring of the Skin by Inducing Myofibroblast Activity.Lentivirus-induced 'Smart' dendritic cells: Pharmacodynamics and GMP-compliant production for immunotherapy against TRP2-positive melanomaInfluence of temperature fluctuations during cryopreservation on vital parameters, differentiation potential, and transgene expression of placental multipotent stromal cells.A future with less HLA: potential clinical applications of HLA-universal cells.Overexpression of the pp32r1 (ANP32C) oncogene or its functional mutant pp32r1Y140H confers enhanced resistance to FTY720 (Finguimod).Determination of unacceptable HLA antigen mismatches in kidney transplant recipients: recommendations of the German Society for Immunogenetics.Granulocyte colony-stimulating factor impairs CD8(+) T cell functionality by interfering with central activation elements.Oncogenic acidic nuclear phosphoproteins ANP32C/D are novel clients of heat shock protein 90.Allogeneic and xenogeneic anti-tumor effect of callithrix jacchus natural killer cells is dependent on NKp30 and B7-H6 interaction.miR-145 Is a Promising Therapeutic Target to Prevent Cornea Scarring.Modulation of heme oxygenase-1 by metalloporphyrins increases anti-viral T cell responses.Red cell allo- and autoimmunisation in transfused sickle cell and cancer patients in Kenyatta National Hospital, Nairobi, Kenya.MHC universal cells survive in an allogeneic environment after incompatible transplantation.HLA-universal platelet transfusions prevent platelet refractoriness in a mouse model.Human calreticulin can act as adjuvant in the maturation of antigen presenting cells.Personalized adoptive immunotherapy for patients with EBV-associated tumors and complications: Evaluation of novel naturally processed and presented EBV-derived T-cell epitopes.Cord blood-derived T cells allow the generation of a more naïve tumor-reactive cytotoxic T-cell phenotype.Semaphorin 3A alters endothelial cell immunogenicity by regulating Class II transactivator activity circuits.Recombinant blood group proteins facilitate the detection of alloantibodies to high-prevalence antigens and reveal underlying antibodies: results of an international study.Differentiation of induced pluripotent stem cell-derived neutrophil granulocytes from common marmoset monkey (Callithrix jacchus).HLA-G mediated immune regulation is impaired by a single amino acid exchange in the alpha 2 domain.HLA-G peptide preferences change in transformed cells: impact on the binding motif.Adoptive transfer of cellular immunity against cytomegalovirus by virus-specific lymphocytes from a third-party family donor.The amino acid variation of HLA-A*02:182 in a highly conserved region is predicted to be functionally similar to HLA-A*02:01:01:01 allele.NKG2A silencing in effector cells to improve effectivity of cell based therapeutics.Dissecting Epstein-Barr Virus-Specific T-Cell Responses After Allogeneic EBV-Specific T-Cell Transfer for Central Nervous System Posttransplant Lymphoproliferative DiseaseHuman leucocyte antigens and pediatric autoimmune liver disease: diagnosis and prognosisCarbamazepine-Mediated Adverse Drug Reactions: CBZ-10,11-epoxide but Not Carbamazepine Induces the Alteration of Peptides Presented by HLA-B∗15:02The polymorphism at residue 156 determines the HLA-B*35 restricted peptide repertoire during HCMV infectionCD28 pro-atherogenic CD4 T-cells explain the link between CMV infection and an increased risk of cardiovascular deathSelective Effects of mTOR Inhibitor Sirolimus on Naïve and CMV-Specific T Cells Extending Its Applicable Range Beyond ImmunosuppressionBetween Innate and Adaptive Immune Responses: NKG2A, NKG2C, and CD8⁺ T Cell Recognition of HLA-E Restricted Self-Peptides Acquired in the Absence of HLA-IaRobust Identification of Suitable T-Cell Subsets for Personalized CMV-Specific T-Cell Immunotherapy Using CD45RA and CD62L MicrobeadsHLA class II antibodies induce necrotic cell death in human endothelial cells via a lysosomal membrane permeabilization-mediated pathwayInhibition of Heme Oxygenase-1 Activity Enhances Wilms Tumor-1-Specific T-Cell Responses in Cancer ImmunotherapyLarge-scale production of megakaryocytes in microcarrier-supported stirred suspension bioreactors.
P50
Q33442786-CD85123D-734E-4C76-A8AD-F43B234026F4Q33573008-6A593526-2EDF-4409-B043-BD25AD575F99Q35723455-47A1DD7C-0CBA-4653-84AD-B4D4EE43B5C7Q35756252-467E2677-6781-4B11-97B9-7254A0D204DCQ35855660-2E7BCAD7-CDC3-443A-8912-267683F3366BQ36031874-07BF39CF-4C55-47BB-897E-6642E76D3B1FQ37693998-AC16DC45-66D2-4E8A-A7CA-5BBBA9910DFFQ38416517-2F0DE53E-A1BB-4F96-90AC-B1E37B03CB15Q38607090-3D44911C-C40D-4FA5-9F23-39CF3688ABEFQ38607420-0328FB4D-6FF0-44DB-B6A7-135ACD40431AQ38785195-4F76A7FB-045C-4C5C-92B5-F34D0A9CC922Q38859902-187289BD-BC14-4867-A986-069BE47912E6Q38977387-59753498-D798-4B46-A26F-5EFB98AD4634Q41112641-27A87AE7-6D82-49C5-8368-440A39F1CB5BQ41750378-E4CABE7C-65E4-4E47-ADE2-B32DE276E1C8Q42015408-38E0C1BA-E5C0-4709-8AB2-BB204F8F0E89Q42223452-8CF12148-FCFF-485B-954C-B51A82F5863FQ43694633-2C93589B-F463-4A83-A277-D1301867347BQ46634313-92F10C53-53F3-4053-8378-2F0CA3F990EDQ49798727-DCCE6E6C-B4B3-466B-A0A0-9A2652C942D5Q50098673-02DEE3D6-C8B8-4CF5-BC00-45F80FD4BC05Q50458797-2B277029-E560-4B39-A4C6-0D88F7C96DCDQ50476611-5B057770-98BE-4FB1-A3A4-7552B18065D9Q51303061-E1BF0F79-C393-44F8-80B5-E7FA3884F785Q52615789-213B1631-529B-49A2-AB74-A04FFED46B15Q53076346-42BB40B0-058F-43CA-90E6-64F1715A722DQ54217693-E06BECAE-EC81-4AE5-94DF-F1414AC1AE1DQ54406605-77C3518E-FFAA-40B7-9BF9-B27BEE465677Q55071214-92C85150-629E-40E7-BC51-42950CE8C58DQ56967496-D3CB4F49-F2DD-4782-ADB7-5D7255F058F8Q57137307-BEBACDBB-33F5-4631-AE7F-C248E094609CQ57300409-0212652A-EBF7-4C9A-9D9A-76952F906761Q58724946-251ECE9B-F480-450E-96C2-77FC74ADD554Q58796708-3E3B5710-B85F-48F8-9812-02F7654273B4Q60951059-4B7CD6C7-CC05-48B8-9E44-50259060F44BQ64062206-903482B6-A1A2-4E10-94C8-6847F62C89B5Q64070853-AC5633F3-B72C-44DA-ACDB-5AEB4FD295E7Q64113679-CD9B58C0-54AC-4C1C-808B-4041D908B563Q64275599-E9FE25CD-6989-481E-8131-8103F859B7DAQ64934930-A2F273BD-71F4-41C4-B27C-89EC51D6309F
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Rainer Blasczyk
@en
Rainer Blasczyk
@nl
type
label
Rainer Blasczyk
@en
Rainer Blasczyk
@nl
prefLabel
Rainer Blasczyk
@en
Rainer Blasczyk
@nl
P31
P496
0000-0003-3875-3190